目的 通过对全球制药行业有代表性的大型并购案例进行归纳分析,以期形成一些国内制药企业在科学制定并购策略与转型发展过程中可借鉴的参考。方法 通过查阅国内外相关文献资料与信息,并结合具体案例研究,对近年全球制药行业并购现状与趋势进行分析归纳。结果与结论 近年来全球制药行业的并购案例数量众多,涉及的并购金额较大。2013至2015年,全球制药企业并购交易数量与金额呈上升趋势,2015年成为近几年来的制药行业并购大年。这其中显现出部分制药企业面临着主要赢利产品专利即将到期,新药研发过程中又遭遇重重困难,面临丰富产品线、扩大市场份额,提升核心竞争力的压力,进一步催生企业合并重组。2016至2017年,并购交易数量和金额出现下降,并购活动从目标对象、并购动因与方式等方面出现不同走向,企业更趋谨慎。笔者通过一些典型案例探讨全球制药行业的并购趋势、并购涉及的主要业务、进行积极并购的药企及其特点等,分析全球制药行业并购现状及发展趋势,可供国内制药企业参考借鉴。

OBJECTIVE To summarize and analyze the representative cases of large-scale mergers and acquisitions in the global pharmaceutical industry in order to form a reference for domestic pharmaceutical companies to use for reference in the scientific development of M&A strategy and transformation.METHODS By reviewing relevant literature and information at home and abroad, and combining specific case studies, the status and trends of mergers and acquisitions in the global pharmaceutical industry in recent years were analyzed.RESULTS AND CONCLUSION In recent years, the number of mergers and acquisitions cases in the global pharmaceutical industry is numerous, and the amount involved in mergers and acquisitions is relatively large. From 2013 to 2015, the number and amount of M&A transactions in global pharmaceutical companies are on the rise. In 2015, it became the year of mergers and acquisitions in the pharmaceutical industry. This shows that some pharmaceutical companies are facing patent expiration of their major profitable products. The new drug development process has encountered many difficulties and faced pressure to expand product lines, expand market share, and increase core competitiveness, further contributing to corporate mergers and reorganizations. From 2016 to 2017, the number and amount of M&A transactions declined, and M&A activities were different from the target audience, M&A motives and methods, and the companies were more cautious. This article discusses mergers and acquisitions trends in the global pharmaceutical industry, major businesses involved in mergers and acquisitions, and active pharmaceutical companies and their characteristics, and analyzes the development trends of global pharmaceutical industry mergers and acquisitions for domestic pharmaceutical companies and industry managers to reference.